Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Enveric Biosciences, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +2 vs. Q3 2024
- Shares held
- 1.08M
- +367.8K (+51.7%) vs. Q3 2024
- Total value
- $386.7K
- +$49.5K (+14.7%) vs. Q3 2024
- New holders
- 3
- 6 more added
- Sold out
- 1
- 4 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENVB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 24 | $736.8K |
| Q1 2026 | 11 | $106.6K |
| Q4 2025 | 11 | $87.7K |
| Q3 2025 | 11 | $232.6K |
| Q2 2025 | 14 | $283.2K |
| Q1 2025 | 15 | $344.7K |
| Q4 2024 | 19 | $386.7K |
| Q3 2024 | 17 | $337.2K |
| Q2 2024 | 17 | $307.3K |
| Q1 2024 | 18 | $488.4K |
| Q4 2023 | 15 | $635.8K |
| Q3 2023 | 15 | $518.3K |
| Q2 2023 | 14 | $631.1K |
| Q1 2023 | 13 | $382.4K |
| Q4 2022 | 12 | $356.8K |
| Q3 2022 | 12 | $623.0K |
| Q2 2022 | 27 | $1.99M |
| Q1 2022 | 31 | $3.61M |
| Q4 2021 | 31 | $4.45M |
| Q3 2021 | 24 | $4.64M |
| Q2 2021 | 18 | $2.72M |
| Q1 2021 | 14 | $3.42M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Enveric Biosciences, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AdvisorShares Investments LLC | 599,854 | $215.0K | 0.04% | +232,807+63.4% | Added |
| Geode Capital Management, LLC | 216,594 | $77.6K | 0.00% | −1,299−0.6% | Reduced |
| UBS Group AG | 78,408 | $28.1K | 0.00% | +77,677+10,626.1% | Added |
| Virtu Financial LLC | 55,763 | $20.0K | 0.00% | +32,646+141.2% | Added |
| Two Sigma Securities, LLC | 31,872 | $11.4K | 0.00% | +1,240+4.0% | Added |
| XTX Topco Ltd | 22,007 | $7.89K | 0.00% | +22,007 | New |
| Vanguard Group Inc | 18,198 | $6.51K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 15,017 | $5.38K | 0.00% | +2,264+17.8% | Added |
| Two Sigma Investments, LP | 12,145 | $4.35K | 0.00% | −1,240−9.3% | Reduced |
| Jane Street Group, LLC | 10,815 | $3.88K | 0.00% | +10,815 | New |
| BlackRock, Inc. | 9,010 | $3.23K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 8,810 | $3.15K | 0.00% | −8,562−49.3% | Reduced |
| Group One Trading, L.P. | 273 | $98 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 180 | $65 | 0.00% | +7+4.0% | Added |
| National Bank of Canada | 70 | $25 | 0.00% | −1−1.4% | Reduced |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 50 | $17 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 19 | $7 | 0.00% | +19 | New |
| Wells Fargo & Company | 16 | $6 | 0.00% | 00.0% | Unchanged |
| Hantz Financial Services, Inc. | 1 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −575−100.0% | Sold out |